SAN FRANCISCO — The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker here.
Designed to be an alternative to topical medications for the treatment of glaucoma, the iDose delivers a novel, uber-potent formulation of travoprost through an implant injected directly into the sclera via a preloaded injector system.
“In using the microfluidic delivery systems that we designed for the MIGS space, we have modified those to get into long-term drug (Read more...)
Uncategorized